Prosecution Insights
Prosecution Insights
Tech Center 2100 • Art Units: 1672 1681 1682 1687 2123
This examiner grants 60% of resolved cases
Mary Chang Leverett serves in Tech Center 2100 and Art Unit 1672. She has 97 resolved cases, resulting in an allowance rate of 60.8 percent. This 60.8 percent rate indicates that more than six out of ten applications in her docket reach issuance. For practitioners, this figure suggests a moderate level of examination difficulty. The 97 resolved cases provide a solid basis for analyzing her prosecution patterns in Tech Center 2100.
The interview lift is 23.8 percent, indicating that interviews are a helpful strategy for advancing cases toward allowance. This 23.8 percent increase in success probability suggests that she is receptive to verbal advocacy. The median days to allowance is 1520. This 1520-day timeline is quite long, suggesting that practitioners should be prepared for a prosecution cycle that lasts over four years on average. Applicants should use the 1520-day figure to manage client expectations and consider the 23.8 percent lift as a valuable tool for overcoming rejections. The combination of a 60.8 percent allowance rate and a 1520-day median indicates that while success is likely, it requires persistent effort over a long period.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17898240 | SYSTEMS AND METHODS FOR IDENTIFYING ADAPTIVE IMMUNE CELL CLONOTYPES | Non-Final OA | 10x Genomics, Inc. |
| 17610788 | ASSESSMENT OF MULTIPLE SIGNALING PATHWAY ACTIVITY SCORE IN AIRWAY EPITHELIAL CELLS TO PREDICT AIRWAY EPITHELIAL ABNORMALITY AND AIRWAY CANCER RISK | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18134518 | Methods And Systems For Identifying Hybrids For Use In Plant Breeding | Non-Final OA | Monsanto Technology LLC |
| 18470568 | METHOD AND SYSTEM FOR IDENTIFYING CANDIDATE GENOME SEQUECNCES BY ESTIMATING COVERAGE | Non-Final OA | Tata Consultancy Services Limited |
| 18069110 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18358001 | GENE MODEL FOR JUDGING PROGNOSIS OF HEPATOCELLULAR CARCINOMA PATIENTS, CONSTRUCTION METHOD AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18281085 | METHODS FOR RECONSTITUTING T CELL SELECTION AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18451739 | DETERMINING A DYNAMIC QUALITY METRIC OF A BIOPSY SAMPLE | Non-Final OA | GUARDANT HEALTH, INC. |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | Non-Final OA | UMC Utrecht Holding B.V. |
| 17876065 | SYSTEM AND METHOD FOR CONTROLLING CELL FUNCTIONING AND MOTILITY WITH THE AID OF A DIGITAL COMPUTER | Non-Final OA | XEROX CORPORATION |
| 17904675 | METHOD AND SYSTEM FOR ADVERSARY RESILIENT SCREENING OF SYNTHETIC GENE ORDERS | Final Rejection | B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY |
| 18174468 | CALIBRATION SEQUENCES FOR NUCLEOTIDE SEQUENCING | Non-Final OA | Illumina, Inc. |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | Final Rejection | UEA ENTERPRISES LIMITED |
| 18080620 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Non-Final OA | SEQUENOM, INC. |
| 17884498 | METHODS AND SYSTEMS FOR TUMOR DETECTION | Non-Final OA | GRAIL, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy